Key Takeaways Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement ...

It is one of a handful of high-profile Bay Area deals to go sour between the drug marketer and Bay Area companies. Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with ...

Shares of Sangamo Therapeutics ($SGMO) came under pressure in Monday’s after-hours trading session after the termination of ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer, which had ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.

Sangamo (SGMO) announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with ...

16:28 EST Sangamo (SGMO) down 31% at $1.61 after Pfizer decision to terminate collaboration Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending ...